BLm Mouse model



We are ready to answer your questions and provide guidance.

BLM Mouse Model



We are ready to answer your questions and provide guidance.

BLEOMycin mouse model

For Pulmonary Fibrosis


The growing amount of people worldwide (with a large proportion being in the US) confirmed infected with COVID-19 remains extremely concerning. Data from previous coronavirus infections, as well as analysis from patients with COVID-19 on discharge from hospital, suggest there could be substantial fibrotic consequences following the SARS-CoV-2 infection. Given the scale of the pandemic, the burden of diseases such as fibro-proliferative ARDS (acute respiratory distress syndrome) and fibrotic interstitial lung disease (ILD)) in the near future is likely to increase significantly. Evidently, there is an urgent need for anti-fibrotic therapies. 

Animal disease models play a pivotal role in developing therapeutics for unmet medicine. Currently, IITRI has developed a ferret infection model to test new vaccine and therapeutics for COVID-19. However, the ferret model has not been used to study pulmonary fibrosis or characterized for anti-fibrotic drug testing. Patients with Idiopathic pulmonary fibrosis (IPF), a chronic, progressive, interstitial lung disease from unknown causes, has been reported to share similar features in patients suffering from COVID-19. In response to the post-pandemic demand for anti-fibrotic drugs, IITRI now offers an improved bleomycin (BLM) induced pulmonary fibrosis mouse model that can recapitulate many of the complex profibrotic responses that are also observed in the lung of IPF and perhaps COVID-19 patients.

It is generally accepted that the current bleomycin mouse model needs to be improved to provide a more progressive fibrosis as is thought to occur in humans. Although administration of a higher BLM dose was shown to cause more severe lung fibrosis, a high mortality (early death) was also observed in such an attempt, hindering the robustness of the model for drug testing. 

Different than the current intra-tracheal BLM mouse model, IITRI has developed a non-invasive intra-bronchial instillation approach to administer BLM predominately to one side of lung. This approach confines the affected lung region so that the high BLM dose can be used to induce more severe pulmonary fibrosis without killing animals.


Benefits of our model

– Our model offers a bigger separation window between sham and BLM mice

– Our model offers a more consistent scale of pulmonary fibrosis in the BLM mice

– Our model can generate a severe active fibrotic phase, mimicking acute exacerbation of IPF

Species Male C57BL/6 mice (8-12 weeks)
Study Duration 14 or 21 days

Intra-bronchial unilateral administration of BLM for disease induction

Endpoints Body weight, lung weight, histopathology of the lungs, BAL cell counts, immunoassays